Endocannabinoid signaling in stress, nausea, and vomiting.
cannabinoid 1 (CB1) receptor
cannabinoid hyperemesis
cyclic vomiting syndrome
endocannabinoid
nausea
stress response
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
revised:
06
08
2024
received:
01
12
2023
accepted:
20
08
2024
medline:
3
9
2024
pubmed:
3
9
2024
entrez:
3
9
2024
Statut:
aheadofprint
Résumé
Classical antiemetics that target the serotonin system may not be effective in treating certain nausea and vomiting conditions like cyclic vomiting syndrome (CVS) and cannabinoid hyperemesis syndrome (CHS). As a result, there is a need for better therapies to manage the symptoms of these disorders, including nausea, vomiting, and anxiety. Cannabis is often used for its purported antiemetic and anxiolytic effects, given regulation of these processes by the endocannabinoid system (ECS). However, there is considerable evidence that cannabinoids can also produce nausea and vomiting and increase anxiety in certain instances, especially at higher doses. This paradoxical effect of cannabinoids on nausea, vomiting, and anxiety may be due to the dysregulation of the ECS, altering how it maintains these processes and contributing to the pathophysiology of CVS or CHS. The purpose of this review is to highlight the involvement of the ECS in the regulation of stress, nausea, and vomiting. We discuss how prolonged cannabis use, such as in the case of CHS or heightened stress, can dysregulate the ECS and affect its modulation of these functions. The review also examines the evidence for the roles of ECS and stress systems' dysfunction in CVS and CHS to better understand the underlying mechanisms of these conditions.
Sections du résumé
BACKGROUND
BACKGROUND
Classical antiemetics that target the serotonin system may not be effective in treating certain nausea and vomiting conditions like cyclic vomiting syndrome (CVS) and cannabinoid hyperemesis syndrome (CHS). As a result, there is a need for better therapies to manage the symptoms of these disorders, including nausea, vomiting, and anxiety. Cannabis is often used for its purported antiemetic and anxiolytic effects, given regulation of these processes by the endocannabinoid system (ECS). However, there is considerable evidence that cannabinoids can also produce nausea and vomiting and increase anxiety in certain instances, especially at higher doses. This paradoxical effect of cannabinoids on nausea, vomiting, and anxiety may be due to the dysregulation of the ECS, altering how it maintains these processes and contributing to the pathophysiology of CVS or CHS.
PURPOSE
OBJECTIVE
The purpose of this review is to highlight the involvement of the ECS in the regulation of stress, nausea, and vomiting. We discuss how prolonged cannabis use, such as in the case of CHS or heightened stress, can dysregulate the ECS and affect its modulation of these functions. The review also examines the evidence for the roles of ECS and stress systems' dysfunction in CVS and CHS to better understand the underlying mechanisms of these conditions.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14911Subventions
Organisme : NIDDK NIH HHS
ID : R13DK135315-01
Pays : United States
Organisme : CIHR
ID : MFE-181788
Pays : Canada
Organisme : Canada First Research Excellence Fund
Informations de copyright
© 2024 The Author(s). Neurogastroenterology & Motility published by John Wiley & Sons Ltd.
Références
Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics. Cancer. 2003;97(11):2880‐2886. doi:10.1002/cncr.11408
Navari RM. Management of chemotherapy‐induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs. 2013;73(3):249‐262. doi:10.1007/s40265-013-0019-1
Kamen C, Tejani MA, Chandwani K, et al. Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol. 2014;722(1):172‐179. doi:10.1016/j.ejphar.2013.09.071
Bhandari S, Venkatesan T. Novel treatments for cyclic vomiting syndrome: beyond ondansetron and amitriptyline. Curr Treat Options Gastroenterol. 2016;14(4):495‐506. doi:10.1007/s11938-016-0114-y
Richards JR. Cannabinoid hyperemesis syndrome: a disorder of the HPA axis and sympathetic nervous system? Med Hypotheses. 2017;103:90‐95. doi:10.1016/j.mehy.2017.04.018
Taranukha T, Charan Suresh Kumar V, Seamon A, Sahr N, Szabo A, Venkatesan T. Depression, young age, chronic marijuana use, and interepisodic symptoms predict psychological distress in patients with cyclic vomiting syndrome. Neurogastroenterol Motil. 2018;30(4):e13245. doi:10.1111/nmo.13245
Andrews PLR, Golding JF, Sanger GJ. An assessment of the effects of neurokinin1 receptor antagonism against nausea and vomiting: relative efficacy, sites of action and lessons for future drug development. Br J Clin Pharmacol. 2023;89:3468‐3490. doi:10.1111/bcp.15852
Cristofori F, Thapar N, Saliakellis E, et al. Efficacy of the neurokinin‐1 receptor antagonist aprepitant in children with cyclical vomiting syndrome. Aliment Pharmacol Ther. 2014;40(3):309‐317. doi:10.1111/apt.12822
Sharkey KA, Darmani NA, Parker LA. Regulation of nausea and vomiting by cannabinoids and the endocannabnoid system. Eur J Pharmacol. 2014;722:134‐146. doi:10.1016/j.ejphar.2013.09.068
Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA. Delta9‐tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol. 2003;285(3):G566‐G576. doi:10.1152/ajpgi.00113.2003
Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009;156(3):397‐411. doi:10.1111/j.1476-5381.2008.00048.x
Green B, Kavanagh D, Young R. Being stoned: a review of self‐reported cannabis effects. Drug Alcohol Rev. 2003;22(4):453‐460. doi:10.1080/09595230310001613976
Allen JH, De Moore G, Heddle R, Twartz J. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53(11):1566‐1570. doi:10.1136/gut.2003.036350
LaFrance EM, Stueber A, Glodosky NC, Mauzay D, Cuttler C. Overbaked: assessing and predicting acute adverse reactions to cannabis. J Cannabis Res. 2020;2(1):2. doi:10.1186/s42238-019-0013-x
Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605‐613.
Breivogel CS, Selley DE, Childers SR. Cannabinoid receptor agonist efficacy for stimulating [35S]GTP gammaS binding to rat cerebellar membranes correlates with agonist‐induced decreases in GDP affinity. J Biol Chem. 1998;273(27):16865‐16873. doi:10.1074/jbc.273.27.16865
Howlett AC, Barth F, Bonner TI, et al. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54(2):161‐202. doi:10.1124/pr.54.2.161
Bisogno T. Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol. 2008;20(SUPPL. 1):1‐9. doi:10.1111/j.1365-2826.2008.01676.x
Herkenham M, Lynn AB, Litrle MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990;87:1932‐1936. doi:10.1073/pnas.87.5.1932
Biegon A, Kerman IA. Autoradiographic study of pre‐ and postnatal distribution of cannabinoid receptors in human brain. Neuroimage. 2001;14(6):1463‐1468. doi:10.1006/nimg.2001.0939
Patel S, Hillard CJ. Role of endocannabinoid signaling in anxiety and depression. Curr Top Behav Neurosci. 2009;1(1):87‐110. doi:10.1007/978-3-540-88955-7
Hyman SM, Sinha R. Stress‐related factors in cannabis use and misuse: implications for prevention and treatment. J Subst Abuse Treat. 2009;36(4):400‐413. doi:10.1016/j.jsat.2008.08.005
Venkatesan T, Hillard CJ, Rein L, Banerjee A, Lisdahl K. Patterns of cannabis use in patients with cyclic vomiting syndrome. Clin Gastroenterol Hepatol. 2020;18(5):1082‐1090.e2. doi:10.1016/j.cgh.2019.07.039
Venkatesan T, Sengupta J, Lodhi A, et al. An internet survey of marijuana and hot shower use in adults with cyclic vomiting syndrome (CVS). Exp Brain Res. 2014;232(8):2563‐2570. doi:10.1007/s00221-014-3967-0
Morena M, Patel S, Bains JS, Hill MN. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology. 2016;41(1):80‐102. doi:10.1038/npp.2015.166
McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res. 2000;886:172‐189. doi:10.1016/S0006-8993(00)02950-4
Hill MN, Tasker JG. Endocannabinoid signaling, glucocorticoid‐mediated negative feedback and regulation of the HPA axis. Neuroscience. 2012;204:5‐16. doi:10.1016/j.neuroscience.2011.12.030
Calhoon GG, Tye KM. Resolving the neural circuits of anxiety. Nat Neurosci. 2015;18(10):1394‐1404. doi:10.1038/nn.4101
McCall JG, Al‐Hasani R, Siuda ER, et al. CRH engagement of the locus coeruleus noradrenergic system mediates stress‐induced anxiety. Neuron. 2015;87(3):605‐620. doi:10.1016/j.neuron.2015.07.002
Gray JM, Vecchiarelli HA, Morena M, et al. Corticotropin‐releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. J Neurosci. 2015;35(9):3879‐3892. doi:10.1523/jneurosci.2737-14.2015
Petrie GN, Balsevich G, Füzesi T, et al. Disruption of tonic endocannabinoid signaling triggers cellular, behavioral and neuroendocrine responses consistent with a stress response. Br J Pharmacol. 2023;180:3146‐3159. doi:10.1111/bph.16198
Gray JM, Wilson CD, Lee TTY, et al. Sustained glucocorticoid exposure recruits cortico‐limbic CRH signaling to modulate endocannabinoid function. Psychoneuroendocrinology. 2016;66:151‐158. doi:10.1016/j.psyneuen.2016.01.004
Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ, College M. Endocannabinoid signaling negatively modulates stress‐ induced activation of the hypothalamic‐pituitary‐ adrenal axis. Endocrinology. 2004;145(12):5431‐5438. doi:10.1210/en.2004-0638
Hill MN, Mclaughlin RJ, Morrish AC, et al. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic‐pituitary‐ adrenal axis. Neuropsychopharmacology. 2009;34(13):2733‐2745. doi:10.1038/npp.2009.114.Suppression
Hill MN, Kumar SA, Filipski SB, et al. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry. 2013;18(10):1125‐1135. doi:10.1038/mp.2012.90
Bluett RJ, Gamble‐george JC, Hermanson DJ, Hartley ND, Marnett LJ, Patel S. Central anandamide deficiency predicts stress‐induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl Psychiatry. 2014;4(7):e408. doi:10.1038/tp.2014.53
Morena M, Aukema RJ, Leitl KD, et al. Upregulation of anandamide hydrolysis in the basolateral complex of amygdala reduces fear memory expression and indices of stress and anxiety. J Neurosci. 2019;39(7):1275‐1292. doi:10.1523/jneurosci.2251-18.2018
Mayo LM, Asratian A, Lindé J, et al. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental medicine trial. Biol Psychiatry. 2020;87(6):538‐547. doi:10.1016/j.biopsych.2019.07.034
Evanson NK, Tasker JG, Hill MN, Hillard CJ, Herman JP. Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling. Endocrinology. 2010;151(10):4811‐4819. doi:10.1210/en.2010-0285
Di S, Malcher‐Lopes R, Halmos KC, Tasker JG. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci. 2003;23(12):4850‐4857.
Shonesy BC, Bluett RJ, Ramikie TS, et al. Genetic disruption of 2‐arachidonoylglycerol synthesis reveals a key role for endocannabinoid signaling in anxiety modulation. Cell Rep. 2014;9(5):1644‐1653. doi:10.1016/j.celrep.2014.11.001
Bedse G, Hartley ND, Neale E, et al. Functional redundancy between canonical endocannabinoid signaling systems in the modulation of anxiety. Biol Psychiatry. 2017;82:488‐499. doi:10.1016/j.biopsych.2017.03.002
Bluett RJ, Baldi R, Haymer A, et al. Endocannabinoid signalling modulates susceptibility to traumatic stress exposure. Nature Commun. 2017;8:14782. doi:10.1038/ncomms14782
Morena M, Leitl KD, Vecchiarelli HA, Gray JM, Campolongo P, Hill MN. Emotional arousal state influences the ability of amygdalar endocannabinoid signaling to modulate anxiety. Neuropharmacology. 2016;111:59‐69. doi:10.1016/j.neuropharm.2016.08.020
Louis‐Gray K, Tupal S, Premkumar LS. TRPV1: a common denominator mediating antinociceptive and antiemetic effects of cannabinoids. Int J Mol Sci. 2022;23(17):10016. doi:10.3390/ijms231710016
Muller C, Morales P, Reggio PH. Cannabinoid ligands targeting TRP channels. Front Mol Neurosci. 2019;11:487. doi:10.3389/fnmol.2018.00487
Sharkey KA, Cristino L, Oland LD, et al. Arvanil, anandamide and N ‐arachidonoyl‐dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci. 2007;25:2773‐2782. doi:10.1111/j.1460-9568.2007.05521.x
Hong S, Zheng G, Wu X, Snider NT, Owyang C, Wiley JW. Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat. Gastroenterology. 2011;140(2):627‐637.e4. doi:10.1053/j.gastro.2010.11.003
Hong S, Fan J, Kemmerer ES, Evans S, Li Y, Wiley JW. Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat. Gut. 2009;58(2):202‐210. doi:10.1136/gut.2008.157594
Socała K, Wlaź P. Evaluation of the antidepressant‐ and anxiolytic‐like activity of α‐spinasterol, a plant derivative with TRPV1 antagonistic effects, in mice. Behav Brain Res. 2016;303:19‐25. doi:10.1016/j.bbr.2016.01.048
Ho KW, Ward NJ, Calkins DJ. TRPV1: a stress response protein in the central nervous system. Am J Neurodegener Dis. 2012;1(1):1‐14.
Marsch R, Foeller E, Rammes G, et al. Reduced anxiety, conditioned fear, and hippocampal long‐term potentiation in transient receptor potential vanilloid type 1 receptor‐deficient mice. J Neurosci. 2007;27(4):832‐839. doi:10.1523/JNEUROSCI.3303-06.2007
Navarria A, Tamburella A, Iannotti FA, et al. The dual blocker of FAAH/TRPV1 N‐arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA‐axis. Pharmacol Res. 2014;87:151‐159. doi:10.1016/j.phrs.2014.04.014
Pavlov VM, Fedotova AY, Andreev YA, Palikov VA, Dyachenko IA. The study of TRPV1 channels of the central nervous system and their effect on anxiety in ICR mice. Dokl Biochem Biophys. 2024:1‐4. doi:10.1134/S1607672924600325
Puder M, Weidenfeld J, Chowers I, Nir I, Conforti N, Siegel RA. Corticotrophin and corticosterone secretion following Δ1‐tetrahydrocannabinol, in intact and in hypothalamic deafferentated male rats. Exp Brain Res. 1982;46(1):85‐88. doi:10.1007/BF00238101
McLaughlin RJ, Hill MN, Gorzalka BB. Monoaminergic neurotransmission contributes to cannabinoid‐induced activation of the hypothalamic‐pituitary‐adrenal axis. Eur J Pharmacol. 2009;624:71‐76. doi:10.1016/j.ejphar.2009.09.055
Papini S, Ruglass LM, Lopez‐Castro T, Powers MB, Smits JAJ, Hien DA. Chronic cannabis use is associated with impaired fear extinction in humans. J Abnorm Psychol. 2017;126(1):117‐124. doi:10.1037/abn0000224
DeVuono MV, La Caprara O, Sullivan MT, et al. Role of the stress response and the endocannabinoid system in Δ9‐tetrahydrocannabinol (THC)‐induced nausea. Psychopharmacology (Berl). 2020;237:2187‐2199. doi:10.1007/s00213-020-05529-5
DeVuono MV, Hrelja KM, Petrie GN, et al. Nausea‐induced conditioned gaping reactions in rats produced by high‐dose synthetic cannabinoid, JWH‐018. Cannabis Cannabinoid Res. 2020;5(4):298‐304. doi:10.1089/can.2019.0103
Cuttler C, Spradlin A, Nusbaum AT, Whitney P, Hinson JM, McLaughlin RJ. Blunted stress reactivity in chronic cannabis users. Psychopharmacology (Berl). 2017;234(15):2299‐2309. doi:10.1007/s00213-017-4648-z
Somaini L, Manfredini M, Amore M, et al. Psychobiological responses to unpleasant emotions in cannabis users. Eur Arch Psychiatry Clin Neurosci. 2012;262(1):47‐57. doi:10.1007/s00406-011-0223-5
Alshaarawy O, Elbaz HA. Cannabis use and blood pressure levels: United States national health and nutrition examination survey, 2005‐2012. J Hypertens. 2016;34(8):1507‐1512. doi:10.1016/j.physbeh.2017.03.040
Venkatesan T, Zadvornova Y, Raff H, Hillard CJ. Endocannabinoid‐related lipids are increased during an episode of cyclic vomiting syndrome. Neurogastroenterol Motil. 2016;28(9):1409‐1418. doi:10.1111/nmo.12843
Shah M, Jergel A, George RP, Jenkins E, Bashaw H. Distinguishing clinical features of cannabinoid hyperemesis syndrome and cyclic vomiting syndrome: a retrospective cohort study. J Pediatr. 2024;271:114054. doi:10.1016/j.jpeds.2024.114054
Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid. J Pharmacol Exp Ther. 2006;318(1):304‐311. doi:10.1124/jpet.106.101287
Rey AA, Purrio M, Viveros MP, Lutz B. Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA B receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology. 2012;37(10):2624‐2634. doi:10.1038/npp.2012.123
Romero J, Berrendero F, Manzanares J, et al. Time‐course of the cannabinoid receptor down‐regulation in the adult rat brain caused by repeated exposure to delta9‐tetrahydrocannabinol. Synapse. 1998;30(3):298‐308.
Rubino T, Viganò D, Premoli F, et al. Changes in the expression of G protein‐coupled receptor kinases and beta‐arrestins in mouse brain during cannabinoid tolerance. Mol Neurobiol. 2006;33(3):199‐213. doi:10.1385/MN:33:3:199
Sim LJ, Hampson RE, Deadwyler SA, Childers SR. Effects of chronic treatment with delta9‐tetrahydrocannabinol on cannabinoid‐stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci. 1996;16(24):8057‐8066. doi:10.1523/JNEUROSCI.16-24-08057.1996
Zhuang S, Kittler J, Grigorenko EV, et al. Effects of long‐term exposure to delta9‐THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Mol Brain Res. 1998;62:141‐149. doi:10.1016/S0169-328X(98)00232-0
McLaughlin RJ, Hill MN, Bambico FR, et al. Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway. Eur Neuropsychopharmacol. 2012;22(9):664‐671. doi:10.1016/j.euroneuro.2012.01.004
Tai S, Hyatt WS, Gu C, et al. Repeated administration of phytocannabinoid Δ9‐THC or synthetic cannabinoids JWH‐018 and JWH‐073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region‐specific manner. Pharmacol Res. 2015;102:22‐32. doi:10.1016/j.phrs.2015.09.006
DeVuono MV, Hrelja KM, Sabaziotis L, et al. Conditioned gaping produced by high dose Δ9‐tetrahydrocannabinol: dysregulation of the hypothalamic endocannabinoid system. Neuropharmacology. 2018;141:272‐282. doi:10.1016/j.neuropharm.2018.08.039
Breivogel CS, Scates SM, Beletskaya IO, Lowery OB, Aceto MD, Martin BR. The effects of Δ9‐tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur J Pharmacol. 2003;459:139‐150. doi:10.1016/S0014-2999(02)02854-6
Dalton VS, Wang H, Zavitsanou K. HU210‐induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat. Neurochem Res. 2009;34(7):1343‐1353. doi:10.1007/s11064-009-9914-y
Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim‐selley LJ. Chronic delta‐9 ‐tetrahydrocannabinol treatment produces a time‐ dependent loss of cannabinoid receptors and cannabinoid receptor‐activated G proteins in rat brain. J Neurochem. 1999;73(6):2447‐2459.
Sim‐Selley LJ, Schechter NS, Rorrer WK, et al. Prolonged recovery rate of CB1 receptor adaptation after cessation of Long‐term cannabinoid administration. Mol PharmacolMol Pharmacol. 2006;70(3):986‐996. doi:10.1124/mol.105.019612
Hirvonen J, Goodwin RS, Li CT, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry. 2012;17(6):642‐649. doi:10.1038/mp.2011.82
Morgan CJA, Page E, Schaefer C, et al. Cerebrospinal fluid anandamide levels, cannabis use and psychotic‐like symptoms. Br J Psychiatry. 2013;202(5):381‐382. doi:10.1192/bjp.bp.112.121178
Ceccarini J, Kuepper R, Kemels D, van Os J, Henquet C, Van Laere K. [18F]MK‐9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict Biol. 2015;20(2):357‐367. doi:10.1111/adb.12116
D'Souza DC, Cortes‐Briones J, Creatura G, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF‐04457845) in the treatment of cannabis withdrawal and dependence in men: a double‐blind, placebo‐controlled, parallel group, phase 2a single‐site randomised controlled trial. Lancet Psychiatry. 2019;6(1):35‐45. doi:10.1016/S2215-0366(18)30427-9
Gorzalka BB, Hill MN, Hillard CJ. Regulation of endocannabinoid signaling by stress: implications for stress‐related affective disorders. Neurosci Biobehav Rev. 2008;32(6):1152‐1160. doi:10.1016/j.neubiorev.2008.03.004
Zorn JV, Schür RR, Boks MP, Kahn RS, Joëls M, Vinkers CH. Psychoneuroendocrinology cortisol stress reactivity across psychiatric disorders: a systematic review and meta‐analysis. Psychoneuroendocrinology. 2017;77:25‐36. doi:10.1016/j.psyneuen.2016.11.036
Hill MN, Patel S, Carrier EJ, et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology. 2005;30(3):508‐515. doi:10.1038/sj.npp.1300601
Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy‐induced nausea and vomiting. Curr Med Res Opin. 2007;23(3):533‐543. doi:10.1185/030079907X167525
May MB, Glode AE. Dronabinol for chemotherapy‐induced nausea and vomiting unresponsive to antiemetics. Cancer Manag Res. 2016;8:49‐55. doi:10.2147/CMAR.S81425
Hornby PJ. Central neurocircuitry associated with emesis. Am J Med. 2001;111(8):106‐112. doi:10.1016/S0002-9343(01)00849-X
Irizarry KJL, Zhong W, Sun Y, Kronmiller BA, Darmani NA. RNA sequencing least shrew (Cryptotis parva) brainstem and gut transcripts following administration of a selective substance P neurokinin NK1 receptor agonist and antagonist expands genomics resources for emesis research. Front Genet. 2023;14:975087. doi:10.3389/fgene.2023.975087
Horn CC, Richardson EJ, Andrews PLR, Friedman MI. Differential effects on gastrointestinal and hepatic vagal afferent fibers in the rat by the anti‐cancer agent cisplatin. Auton Neurosci. 2004;115(1–2):74‐81. doi:10.1016/j.autneu.2004.08.011
Darmani NA. Delta‐9‐tetrahydrocannabinol differentially suppresses cisplatin‐induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacol Biochem Behav. 2001;69:239‐249. doi:10.1016/S0091-3057(01)00531-7
Darmani NA, Janoyan JJ, Crim J, Ramirez J. Receptor mechanism and antiemetic activity of structurally‐diverse cannabinoids against radiation‐induced emesis in the least shrew. Eur J Pharmacol. 2007;563(1–3):187‐196. doi:10.1016/j.ejphar.2007.01.093
Kwiatkowska M, Parker LA, Burton P, Mechoulam R. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin‐induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology (Berl). 2004;174(2):254‐259. doi:10.1007/s00213-003-1739-9
Parker LA, Kwiatkowska M, Burton P, Mechoulam R. Effect of cannabinoids on lithium‐induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology (Berl). 2004;171:156‐161. doi:10.1007/s00213-003-1571-2
Cluny NL, Naylor RJ, Whittle BA, Javid FA. The effects of cannabidiol and tetrahydrocannabinol on motion‐induced emesis in Suncus murinus. Basic Clin Paharmacol Toxicol. 2008;103:150‐156. doi:10.1111/j.1742-7843.2008.00253.x
Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310(5746):329‐332. doi:10.1126/science.1115740
Parker LA, Limebeer CL, Rock EM, Litt DL, Kwiatkowska M, Piomelli D. The FAAH inhibitor URB‐597 interferes with cisplatin‐ and nicotine‐induced vomiting in the Suncus murinus (house musk shrew). Physiol Behav. 2009;97(1):121‐124. doi:10.1016/j.physbeh.2009.02.014
Sticht MA, Long JZ, Rock EM, et al. Inhibition of monoacylglycerol lipase attenuates vomiting in Suncus murinus and 2‐arachidonoyl glycerol attenuates nausea in rats. Br J Pharmacol. 2012;165(8):2425‐2435. doi:10.1111/j.1476-5381.2011.01407.x
Häring M, Grieb M, Monory K, Lutz B, Moreira FA. Cannabinoid CB1 receptor in the modulation of stress coping behavior in mice: the role of serotonin and different forebrain neuronal subpopulations. Neuropharmacology. 2013;65:83‐89. doi:10.1016/j.neuropharm.2012.09.002
Häring M, Marsicano G, Lutz B, Monory K. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience. 2007;146(3):1212‐1219. doi:10.1016/j.neuroscience.2007.02.021
Rudd JA, Nalivaiko E, Matsuki N, Wan C, Andrews PLR. The involvement of TRPV1 in emesis and anti‐emesis. Temperature. 2015;2(2):258‐276. doi:10.1080/23328940.2015.1043042
Darmani NA, Belkacemi L, Zhong W. Δ9‐THC and related cannabinoids suppress substance P‐ induced neurokinin NK1‐receptor‐mediated vomiting via activation of cannabinoid CB1 receptor. Eur J Pharmacol. 2019;865:172806. doi:10.1016/j.ejphar.2019.172806
Roscoe JA, Morrow GR, Hickok JT, Stern RM. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy‐induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage. 2000;20(2):113‐121. doi:10.1016/S0885-3924(00)00159-7
Andrews PLR, Horn CC. Signals for nausea and emesis: implications for models of upper gastrointestinal diseases. Auton Neurosci. 2006;125(1–2):100‐115. doi:10.1016/j.autneu.2006.01.008
Zhong W, Shahbaz O, Teskey G, et al. Mechanisms of nausea and vomiting: current knowledge and recent advances in intracellular emetic signaling systems. Int J Mol Sci. 2021;22(11):5797. doi:10.3390/ijms22115797
Tramèr MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323(7303):16‐21. doi:10.1136/bmj.323.7303.16
Santana TA, Trufelli DC, de Matos LL, Cruz FM, Del Giglio A. Meta‐analysis of adjunctive non‐NK1 receptor antagonist medications for the control of acute and delayed chemotherapy‐induced nausea and vomiting. Support Care Cancer. 2015;23(1):213‐222. doi:10.1007/s00520-014-2392-z
Stith SS, Li X, Orozco J, et al. The effectiveness of common cannabis products for treatment of nausea. J Clin Gastroenterol. 2022;56(4):331‐338. doi:10.1097/MCG.0000000000001534
Parker LA. Conditioned flavor avoidance and conditioned gaping: rat models of conditioned nausea. Eur J Pharmacol. 2014;722(1):122‐133. doi:10.1016/j.ejphar.2013.09.070
Grill HJ, Norgren R. The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res. 1978;143(2):263‐279. doi:10.1016/0006-8993(78)90568-1
Travers JB, Norgren R. Electromyographic analysis of the ingestion and rejection of sapid stimuli in the rat. Behav Neurosci. 1986;100(4):544‐555. doi:10.1037/0735-7044.100.4.544
Napadow V, Sheehan JD, Kim J, et al. The brain circuitry underlying the temporal evolution of nausea in humans. Cereb Cortex. 2013;23(4):806‐813. doi:10.1093/cercor/bhs073
Sclocco R, Kim J, Garcia RG, et al. Brain circuitry supporting multi‐organ autonomic outflow in response to nausea. Cereb Cortex. 2016;26(2):485‐497. doi:10.1093/cercor/bhu172
Aguilar‐Rivera M, Kim S, Coleman TP, Maldonado PE, Torrealba F. Interoceptive insular cortex participates in sensory processing of gastrointestinal malaise and associated behaviors. Sci Rep. 2020;10(1):21642. doi:10.1038/s41598-020-78200-w
Moldrich G, Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides. 2000;21(11):1735‐1742. doi:10.1016/s0196-9781(00)00324-7
Hietala J, Nyman MJ, Eskola O, et al. Visualization and quantification of neurokinin‐1 (NK1) receptors in the human brain. Mol Imaging Biol. 2005;7(4):262‐272. doi:10.1007/s11307-005-7001-6
Allen GV, Saper CB, Hurley KM, Cechetto DF. Organization of visceral and limbic connections in the insular cortex of the rat. J Comp Neurol. 1991;311(1):1‐16. doi:10.1002/cne.903110102
Yasui Y, Breder CD, Saper CB, Al YET. Autonomic responses and efferent pathways from the insular cortex in the rat. J Comp Neurol. 1991;303:355‐374. doi:10.1002/cne.903030303
Limebeer CL, Rock EM, Sharkey KA, Parker LA. Nausea‐induced 5‐HT release in the interoceptive insular cortex and regulation by monoacylglycerol lipase (MAGL) inhibition and cannabidiol. eNeuro. 2018;5(4):1‐10. doi:10.1523/ENEURO.0256-18.2018
Tuerke KJ, Limebeer CL, Fletcher PJ, Parker LA. Double dissociation between regulation of conditioned disgust and taste avoidance by serotonin availability at the 5‐HT3 receptor in the posterior and anterior insular cortex. J Neurosci. 2012;32(40):13709‐13717. doi:10.1523/JNEUROSCI.2042-12.2012
Limebeer CL, Parker LA. Delta‐9‐tetrahydrocannabinol interferes with the establishment and the expression of conditioned rejection reactions produced by cyclophosphamide: a rat model of nausea. Neuroreport. 1999;10:3769‐3772.
Parker LA, Mechoulam R, Schlievert C, Abbott L, Fudge ML, Burton P. Effects of cannabinoids on lithium‐induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology (Berl). 2003;166(2):156‐162. doi:10.1007/s00213-002-1329-2
Limebeer CL, Rock EM, Mechoulam R, Parker LA. The anti‐nausea effects of CB1 agonists are mediated by an action at the visceral insular cortex. Br J Pharmacol. 2012;167(5):1126‐1136. doi:10.1111/j.1476-5381.2012.02066.x
Parker LA, Niphakis MJ, Downey R, et al. Effect of selective inhibition of monoacylglycerol lipase (MAGL) on acute nausea, anticipatory nausea, and vomiting in rats and Suncus murinus. Psychopharmacology (Berl). 2015;232(3):583‐593. doi:10.1007/s00213-014-3696-x
Sticht MA, Limebeer CL, Rafla BR, et al. Endocannabinoid regulation of nausea is mediated by 2‐arachidonoylglycerol (2‐AG) in the rat visceral insular cortex. Neuropharmachology. 2016;102:92‐102. doi:10.1245/s10434-014-3918-9
Sticht MA, Limebeer CL, Rafla BR, Parker LA. Intra‐visceral insular cortex 2‐arachidonoylglycerol, but not N‐arachidonoylethanolamide, suppresses acute nausea‐induced conditioned gaping in rats. Neuroscience. 2015;286:338‐344. doi:10.1016/j.neuroscience.2014.11.058
Rock EM, Limebeer CL, Ward JM, et al. Interference with acute nausea and anticipatory nausea in rats by fatty acid amide hydrolase (FAAH) inhibition through a PPARα and CB1 receptor mechanism, respectively: a double dissociation. Psychopharmacology (Berl). 2015;232(20):3841‐3848. doi:10.1007/s00213-015-4050-7
Rock EM, Moreno‐Sanz G, Limebeer CL, et al. Suppression of acute and anticipatory nausea by peripherally restricted fatty acid amide hydrolase inhibitor in animal models: role of PPARα and CB1 receptors. Br J Pharmacol. 2017;174(21):3837‐3847. doi:10.1111/bph.13980
Vaziri ND, Thomas R, Stearling M, et al. Toxicity with intravenous injection of crude marijuana extract. Clin Toxicol. 1981;18(3):353‐366.
Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non‐cancer pain: results of a prospective survey. Pain. 2003;102(1):211‐216. doi:10.1016/s0304-3959(02)00400-1
Karila L, Roux P, Rolland B, et al. Acute and long‐term effects of cannabis use: a review. Curr Pharm Des. 2014;20:4112‐4118.
Fallon MT, Lux EA, Mcquade R, et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double‐blind, randomized, placebo‐controlled phase 3 studies. Br J Pain. 2017;11(3):119‐133. doi:10.1177/2049463717710042
Johal H, Devji T, Chang Y, Simone J, Vannabouathong C, Bhandari M. Cannabinoids in chronic non‐cancer pain: a systematic review and meta‐analysis. Clin Med Insights Arthritis Musculoskelet Disord. 2020;13:1179544120906461. doi:10.1177/1179544120906461
Venkatesan T, Levinthal DJ, Li BUK, et al. Role of chronic cannabis use: cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome. Neurogastroenterol Motil. 2019;31(S2):e13606. doi:10.1111/nmo.13606
Wasilewski A, Lewandowska U, Mosinska P, et al. Cannabinoid receptor type 1 and mu‐opioid receptor polymorphisms are associated with cyclic vomiting syndrome. Am J Gastroenterol. 2017;112(6):933‐939. doi:10.1038/ajg.2017.73
Scheckel CL, Boff E, Dahlen P, Smart T. Behavioral effects in monkeys of racemates of two biologically active marijuana constituents. Science. 1968;160(3835):1467‐1469.
Hockman CH, Perrin RG, Kalant H. Electroencephalographic and behavioral alterations produced by delta ‐ 9‐tetrahydrocannabinol. Science. 1971;172(3986):968‐970.
Shannon HE, Martin WR, Silcox D. Lack of antiemetic effects of delta‐9‐tetrahydrocannabinol in apomorphine‐induced emesis in the dog. Life Sci. 1978;23:49‐53.
Parker LA, Gillies T. THC‐induced place and taste aversions in Lewis and Sprague‐Dawley rats. Behav Neurosci. 1995;109(1):71‐78.
Richards JR, Gordon BK, Danielson AR, Moulin AK. Pharmacologic treatment of cannabinoid hyperemesis syndrome: a systematic review. Pharmacotherapy. 2017;37:725‐734. doi:10.1002/phar.1931
Richards JR, Dutczak O. Propranolol treatment of cannabinoid hyperemesis syndrome. J Clin Psychopharmacol. 2017;37(4):482‐484. doi:10.1097/JCP.0000000000000735
Hayes WJ, VanGilder D, Berendse J, Lemon MD, Kappes JA. Cyclic vomiting syndrome: diagnostic approach and current management strategies. Clin Exp Gastroenterol. 2018;11:77‐84.
Tarbell SE, Shaltout HA, Wagoner AL, Diz DI, Fortunato JE. Relationship among nausea, anxiety, and orthostatic symptoms in pediatric patients with chronic unexplained nausea. Exp Brain Res. 2014;232(8):2645‐2650. doi:10.1007/s00221-014-3981-2
DeVuono MV, Parker LA. Cannabinoid hyperemesis syndrome : a review of potential mechanisms. Cannabis Cannabinoid Res. 2020;5:132‐144. doi:10.1089/can.2019.0059
Andrykowski MA. The role of anxiety in the development of anticipatory nausea in cancer chemotherapy: a review and synthesis. Psychosom Med. 1990;52(4):458‐475. doi:10.1097/00006842-199007000-00008
Levinthal DJ, Bielefeldt K. Adult cyclical vomiting syndrome: a disorder of allostatic regulation? Exp Brain Res. 2014;232(8):2541‐2547. doi:10.1007/s00221-014-3939-4
Mosa ASM, Hossain AM, Lavoie BJ, Yoo I. Patient‐related risk factors for chemotherapy‐induced nausea and vomiting: a systematic review. Front Pharmacol. 2020;11:329. doi:10.3389/fphar.2020.00329
Friesen C, Singh M, Singh V, Schurman JV. A cross‐sectional study of nausea in functional abdominal pain: relation to mucosal mast cells and psychological functioning. BMC Gastroenterol. 2020;20(1):144. doi:10.1186/s12876-020-01291-2
Nguyen L, Wilson LA, Miriel L, et al. Autonomic function in gastroparesis and chronic unexplained nausea and vomiting: relationship with etiology, gastric emptying, and symptom severity. Neurogastroenterol Motil. 2020;32:e13810. doi:10.1111/nmo.13810
Wilson PB, Russell H, Pugh J. Anxiety may be a risk factor for experiencing gastrointestinal symptoms during endurance races: an observational study. Eur J Sport Sci. 2021;21(3):421‐427. doi:10.1080/17461391.2020.1746836
Levinthal DJ, Romutis S, Rajalaban A, et al. Greater intolerance to uncertainty predicts poorer quality of life in adults with cyclic vomiting syndrome. Neurogastroenterol Motil. 2021;33(12):e14159. doi:10.1111/nmo.14159
Pélissier F, Claudet I, Gandia‐Mailly P, Benyamina A, Franchitto N. Cannabis hyperemesis syndrome in the emergency department: how can a specialized addiction team be useful? A pilot study. J Emerg Med. 2016;51(5):544‐551. doi:10.1016/j.jemermed.2016.06.009
Bhandari S, Venkatesan T. Clinical characteristics, comorbidities and hospital outcomes in hospitalizations with cyclic vomiting syndrome: a Nationwide analysis. Dig Dis Sci. 2017;62(8):2035‐2044. doi:10.1007/s10620-016-4432-7
Parikh SV, Segal ZV, Grigoriadis S, et al. Canadian network for mood and anxiety treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord. 2009;117(Suppl 1):S15‐S25. doi:10.1016/j.jad.2009.06.042
Venkatesan T, Hillard CJ, Ayer L, et al. Acute and long‐term effects of app‐delivered heartfulness meditation on psychological outcomes and the endocannabinoid signaling system in cyclic vomiting syndrome. Clin Transl Gastroenterol. 2024;15(7):e00711. doi:10.14309/ctg.0000000000000711
Hasler WL, Levinthal DJ, Tarbell SE, et al. Cyclic vomiting syndrome: pathophysiology, comorbidities, and future research directions. Neurogastroenterol Motil. 2019;31(S2):e13607. doi:10.1111/nmo.13607
Otto B, Riepl RL, Klosterhalfen S, Enck P. Endocrine correlates of acute nausea and vomiting. Auton Neurosci. 2006;129(1–2):17‐21. doi:10.1016/j.autneu.2006.07.010
Venkatesan T, Prieto T, Barboi A, et al. Autonomic nerve function in adults with cyclic vomiting syndrome: a prospective study. Neurogastroenterol Motil. 2010;22(12):1303‐1308. doi:10.1111/j.1365-2982.2010.01577.x
McEwen BS. Allostasis and allostatic load: implications for neuropsychopharmacology. In: Hyman SE, ed. The Science of Mental Health: Stress and the Brain. Vol 9. Routledge; 2013:2‐18.
Kumar N, Bashar Q, Reddy N, et al. Cyclic vomiting syndrome (CVS): is there a difference based on onset of symptoms ‐ pediatric versus adult? BMC Gastroenterol. 2012;12(1):52. doi:10.1186/1471-230X-12-52
Bashashati M, Bradshaw HB, Johnson CT, et al. Plasma endocannabinoids and cannabimimetic fatty acid derivatives are altered in cyclic vomiting syndrome: the effects of sham feeding. J Invest Med. 2023;71(8):821‐829. doi:10.1177/10815589231196591
Richards JR, Lapoint JM, Burillo‐Putze G. Cannabinoid hyperemesis syndrome: potential mechanisms for the benefit of capsaicin and hot water hydrotherapy in treatment. Clin Toxicol. 2018;56(1):15‐24. doi:10.1080/15563650.2017.1349910
Murphy LM, Whelan AR, Griffin LB, Hamel MS. A pilot randomized control trial of topical capsaicin as adjunctive therapy for nausea and vomiting of pregnancy. Am J Obstet Gynecol MFM. 2023;5(7):100997. doi:10.1016/j.ajogmf.2023.100997
Mooventhan A, Nivethitha L. Scientific evidence‐based effects of hydrotherapy on various systems of the body. N Am J Med Sci. 2014;6(5):199‐209. doi:10.4103/1947
Hoppe JM, Frick A, Åhs F, et al. Association between amygdala neurokinin‐1 receptor availability and anxiety‐related personality traits. Transl Psychiatry. 2018;8(1):168. doi:10.1038/s41398-018-0163-1
Hassanzadeh P, Hassanzadeh A. Involvement of the neurotrophin and cannabinoid systems in the mechanisms of action of neurokinin receptor antagonists. Eur Neuropsychopharmacol. 2011;21(12):905‐917. doi:10.1016/j.euroneuro.2011.01.002
Heldt SA, Davis M, Ratti E, Corsi M, Trist D, Ressler KJ. Anxiolytic‐like effects of the neurokinin 1 receptor antagonist GR‐205171 in the elevated plus‐maze and contextual fear‐potentiated startle model of anxiety in gerbils. Behav Pharmacol. 2009;20(7):584‐595. doi:10.1097/FBP.0b013e32832ec594
Tillisch K, Labus J, Nam B, et al. Neurokinin‐1‐receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study. Aliment Pharmacol Ther. 2012;35(3):360‐367. doi:10.1111/j.1365-2036.2011.04958.x
Zhang G, Chen W, Lao L, Marvizón JCG. Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization. Eur J Neurosci. 2010;31(2):225‐237. doi:10.1111/j.1460-9568.2009.07075.x
Witsil JC, Mycyk MB. Haloperidol, a novel treatment for cannabinoid hyperemesis syndrome. Am J Ther. 2017;24(1):e64‐e67. doi:10.1097/MJT.0000000000000157
Belkacemi L, Darmani NA. Dopamine receptors in emesis: molecular mechanisms and potential therapeutic function. Pharmacol Res. 2020;161:105124. doi:10.1016/j.phrs.2020.105124
Lupica CR, Riegel AC, Hoffman AF. Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol. 2004;143(2):227‐234. doi:10.1038/sj.bjp.0705931
Kibret BG, Canseco‐Alba A, Onaivi ES, Engidawork E. Crosstalk between the endocannabinoid and mid‐brain dopaminergic systems: implication in dopamine dysregulation. Front Behav Neurosci. 2023;17:1137957. doi:10.3389/fnbeh.2023.1137957